COST-EFFECTIVENESS OF LIRAGLUTIDE FOR SUBJECTS WITH TYPE 2 DIABETES IN SPAIN

被引：0
|
作者：
Ramirz de Arellano, A. [1 ]
Hunt, B. [2 ]
Mezquita Raya, P. [3 ]
Briones, T. [1 ]
Perez, A. [1 ,4 ]
Valentine, W. J. [2 ]
机构：
[1] Novo Nordisk Pharma SA, Madrid, Spain
[2] Ossian Hlth Econ & Commun, Basel, Switzerland
[3] Hosp Torrecardenas, Clin San Pedro, Almeria, Spain
[4] Hosp Santa Creu & Sant Pau, Barcelona, Spain
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 03期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PDB69
引用
收藏
页码：A249 / A250
页数：2
相关论文
共 50 条
  • [41] Cost Effectiveness of Liraglutide in Type II Diabetes: A Systematic Review
    Patrick M. Zueger
    Neil M. Schultz
    Todd A. Lee
    PharmacoEconomics, 2014, 32 : 1079 - 1091
  • [42] Lifetime health consequences and cost-effectiveness of rosiglitazone in combination with metformin for the treatment of type 2 diabetes in Spain
    Shearer A.T.
    Bagust A.
    Ampudia-Blasco F.J.
    Álvarez B.M.-L.
    Escolano I.P.
    París G.
    PharmacoEconomics, 2006, 24 (Suppl 1) : 49 - 59
  • [43] Clinical and cost-effectiveness of Rosiglitazone-Metformin combination in patients with Type-2 Diabetes in Spain
    Shearer, A
    Bagust, A
    Ampudia-Blasco, J
    Martinez-Lage, B
    DIABETES, 2004, 53 : A293 - A293
  • [44] THE COST-EFFECTIVENESS OF SAXAGLIPTIN WHEN ADED TO METFORMIN AND SULPHONYLUREA IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS IN SPAIN
    Sanchez-Covisa, J.
    Franch, J.
    Mauricio, D.
    Lopez-Martinez, N.
    Chuang, L. H.
    Capel, M.
    VALUE IN HEALTH, 2014, 17 (07) : A350 - A350
  • [45] THE COST-EFFECTIVENESS ANALYSIS OF VIDALGLIPTIN IN TYPE 2 DIABETES IN POLAND
    Walczak, J.
    Nogas, G.
    Gebus, E.
    Pawlik, D.
    Pacocha, K.
    VALUE IN HEALTH, 2009, 12 (07) : A406 - A406
  • [46] Screening for type 2 diabetes mellitus: A cost-effectiveness analysis
    Hoerger, TJ
    Harris, R
    Hicks, KA
    Donahue, K
    Sorensen, S
    Engelgau, M
    ANNALS OF INTERNAL MEDICINE, 2004, 140 (09) : 689 - 699
  • [47] US Cost-Effectiveness of Saxagliptin in Type 2 Diabetes Mellitus
    Bergenheim, Klas
    Williams, Setareh A.
    Bergeson, Joette Gdovin
    Stern, Lee
    Sriprasert, Michelle
    AMERICAN JOURNAL OF PHARMACY BENEFITS, 2012, 4 (01) : 20 - 28
  • [48] Cost-effectiveness of saxagliptin (Onglyza®) in type 2 diabetes in Sweden
    Granstrom, Ola
    Bergenheim, Klas
    McEwan, Phil
    Sennfalt, Karin
    Henriksson, Martin
    PRIMARY CARE DIABETES, 2012, 6 (02) : 127 - 136
  • [49] COST-EFFECTIVENESS OF NEW ANTIDIABETICS IN TYPE 2 DIABETES: A REVIEW
    Baytar, S.
    Malhan, S.
    VALUE IN HEALTH, 2010, 13 (07) : A292 - A292
  • [50] Cost-Effectiveness of Saxagliptin in Type 2 Diabetes in the United States
    Bergenheim, Klas
    Williams, Setareh A.
    Bergeson, Joette G.
    Stern, Lee
    Sriprasert, Michelle
    DIABETES, 2011, 60 : A629 - A630
12345